Identifying genetic markers for better treatment of B-cell lymphoma
Genetic and Epigenetic Biomarkers for B-cell Lymphoma
This study is looking at how certain genes might help doctors understand how well patients with diffuse large B-cell lymphoma (DLBCL) will respond to common treatments, so they can improve care and outcomes for everyone affected by this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10674524 on NIH RePORTER |
What this research studies
This research focuses on diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma in the U.S. The study aims to identify genetic and epigenetic biomarkers that can help predict how patients will respond to standard treatments like R-CHOP. By analyzing the TP53 gene and its role in tumor behavior, researchers hope to improve prognosis and treatment strategies for patients with DLBCL. The approach involves collaboration with multiple medical centers to gather comprehensive data on patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with diffuse large B-cell lymphoma who are undergoing or have completed treatment.
Not a fit: Patients with other types of lymphoma or those who do not have a diagnosis of diffuse large B-cell lymphoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans for patients with B-cell lymphoma, improving survival rates.
How similar studies have performed: Previous research has shown promise in using genetic markers to predict treatment outcomes in various cancers, suggesting that this approach could be effective for DLBCL as well.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Young, Ken H. — Duke University
- Study coordinator: Young, Ken H.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.